STSA
Price:
$1.1
Market Cap:
$36.47M
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.[Read more]
Industry
Biotechnology
IPO Date
2019-09-13
Stock Exchange
NASDAQ
Ticker
STSA
According to Satsuma Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is 125.24%. This represents a change of -941.13% compared to the average of -14.89% of the last 4 quarters.
The mean historical ROE of Satsuma Pharmaceuticals, Inc. over the last ten years is 42.80%. The current 125.24% ROE has changed 192.62% with respect to the historical average. Over the past ten years (40 quarters), STSA's ROE was at its highest in in the December 2018 quarter at 19.32%. The ROE was at its lowest in in the March 2023 quarter at -26.08%.
Average
42.80%
Median
56.60%
Minimum
-50.59%
Maximum
95.21%
Discovering the peaks and valleys of Satsuma Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 9.52%
Maximum Annual ROE = 95.21%
Minimum Annual Increase = -196.10%
Minimum Annual ROE = -50.59%
Year | ROE | Change |
---|---|---|
2022 | 32.66% | -164.56% |
2021 | -50.59% | -196.10% |
2020 | 52.64% | -20.62% |
2019 | 66.31% | 9.52% |
2018 | 60.55% | -36.41% |
The current ROE of Satsuma Pharmaceuticals, Inc. (STSA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
11.57%
5-year avg
32.31%
10-year avg
42.80%
Satsuma Pharmaceuticals, Inc.’s ROE is less than ZIVO Bioscience, Inc. (618.61%), greater than Theseus Pharmaceuticals, Inc. (-12.35%), greater than Erasca, Inc. (-42.26%), greater than Forte Biosciences, Inc. (-151.43%), greater than Applied Molecular Transport Inc. (-131.59%), greater than SAB Biotherapeutics, Inc. (-94.37%), greater than Senti Biosciences, Inc. (-154.84%), greater than Cingulate Inc. (-113174.53%), less than Bellicum Pharmaceuticals, Inc. (33.22%), greater than Hillstream BioPharma, Inc. (-172.28%), greater than Kronos Bio, Inc. (-64.55%), greater than Cyclerion Therapeutics, Inc. (-55.31%), greater than Larimar Therapeutics, Inc. (-35.87%), less than Addex Therapeutics Ltd (92.06%), greater than Achilles Therapeutics plc (-54.57%), greater than Assembly Biosciences, Inc. (-121.46%), greater than CytomX Therapeutics, Inc. (-41.34%), greater than Instil Bio, Inc. (-37.44%), greater than Neoleukin Therapeutics, Inc. (-8.54%), greater than PMV Pharmaceuticals, Inc. (-24.20%), less than Eliem Therapeutics, Inc. (0%), greater than MediciNova, Inc. (-20.70%), greater than Pharvaris N.V. (-38.27%), greater than PepGen Inc. (-60.17%),
Company | ROE | Market cap |
---|---|---|
618.61% | $78.37M | |
-12.35% | $181.50M | |
-42.26% | $726.61M | |
-151.43% | $28.80M | |
-131.59% | $11.01M | |
-94.37% | $461.46K | |
-154.84% | $19.13M | |
-113174.53% | $15.61M | |
33.22% | $778.33K | |
-172.28% | $4.17M | |
-64.55% | $57.32M | |
-55.31% | $8.92M | |
-35.87% | $241.19M | |
92.06% | $11.45M | |
-54.57% | $46.85M | |
-121.46% | $93.56M | |
-41.34% | $83.74M | |
-37.44% | $142.85M | |
-8.54% | $8.20M | |
-24.20% | $76.07M | |
0% | $342.68M | |
-20.70% | $101.53M | |
-38.27% | $1.02B | |
-60.17% | $131.36M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Satsuma Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Satsuma Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Satsuma Pharmaceuticals, Inc.'s ROE?
How is the ROE calculated for Satsuma Pharmaceuticals, Inc. (STSA)?
What is the highest ROE for Satsuma Pharmaceuticals, Inc. (STSA)?
What is the 3-year average ROE for Satsuma Pharmaceuticals, Inc. (STSA)?
What is the 5-year average ROE for Satsuma Pharmaceuticals, Inc. (STSA)?
How does the current ROE for Satsuma Pharmaceuticals, Inc. (STSA) compare to its historical average?